Qian Hao
6 Papers
Qian Hao is an academic researcher. The author has contributed to research in topics: Internal medicine & Computer science. The author has co-authored 1 publications.
Chat about Author
Papers
Breast cancer is associated with coronary heart disease: a cross-sectional survey of NHANES 1999–2018
Luyao Dai,Ruoxuan Li,Qian Hao,Yaohui Zhang,Huafeng Kang,Xiaobin Ma,Yafan Song +6 more
TL;DR: It is necessary to screen patients with CHD for BC and monitor BC survivors for the long-term risk of developing CHD, as this study demonstrates the close relationship between CHD and female BC.
1
Low-density lipoprotein: a versatile nanoscale platform for targeted delivery
Luyao Dai,Shuaijun Li,Qian Hao,Ruina Zhou,Huiyang Zhou,Wenxi Lei,Huafeng Kang,Hao Wu,Yuanpei Li,Xiaobin Ma +9 more
TL;DR: In this paper , the authors introduce the structure, composition, advantages, defects, and reconstruction of LDL delivery systems, summarize their research status and progress in targeted diagnosis and therapy, and finally look forward to the clinical application of LDL as an effective delivery vehicle.
A Multistage‐Responsive Antibody‐Delivery Strategy to Improve Immunotherapy for NSCLC Brain Metastasis by Ultrasensitive Releasing and Tumor‐Anchoring
Shuaijun Li,Caiting Meng,Qian Hao,Luyao Dai,Jiahong Shi,Ji Xu,Xin Zhou,Sitong Zhao,Jinfan Yang,Huafeng Kang,Yuzhu Hou,Mingzhen Zhang,Xiaobin Ma,Mingqian Tan,Hao Wu +14 more
TL;DR: Two in vivo ICB therapy studies show a significant tumor growth inhibition from the MB‐aPDL1 with an encouraging cure rate of 20% for the NSCLC brain metastases, due to enhanced immune response in tumor, commendably with less behavioral adverse reactions and liver damage.
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
Qian Hao,Lidan Chang,Dingli Song,Dandan Liu,Xiaobin Ma,Hao Wu,Huafeng Kang +6 more
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures.
Lidan Chang,Dandan Liu,Xuyan Zhao,Luyao Dai,Xueting Ren,Qian Hao,Peinan Liu,Hao Wu,Xiaobin Ma,Huafeng Kang +9 more
TL;DR: The findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, hormone receptor-negative, or hormone receptor negativity.